Joy Odeta
Family Medicine · Hope, INNPI 1447409255
Payments from drug & device makers
Across 137 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$387
- Amgen$240
- Exact Sciences$145
- AbbVie$128
- Lilly USA, LLC$128
- Biohaven Pharmaceutical Holding Company Ltd.$125
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,36095%
- Education$1165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- Ozempic$116
How this compares
$2,476 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $175,300 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $132,943 |
| FarxigaDapagliflozin Propanediol | 66 | $92,730 |
| MounjaroTirzepatide | 55 | $63,426 |
| EliquisApixaban | 32 | $33,813 |
| JardianceEmpagliflozin | 23 | $27,272 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $23,457 |
| TradjentaLinagliptin | 13 | $19,061 |
| Repatha SyringeEvolocumab | 18 | $15,456 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $15,423 |
| XareltoRivaroxaban | 11 | $15,161 |
| Repatha SureclickEvolocumab | 18 | $12,013 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $11,526 |
| TrulicityDulaglutide | 11 | $10,620 |
| Dexlansoprazole DrDexlansoprazole | 50 | $9,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $387 | $175,300168 claims |
| GSKTrelegy Ellipta | $57 | $132,943166 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $67 | $116,18791 claims |
| Lilly USA, LLCMounjaro, Trulicity | $128 | $74,04566 claims |
| Boehringer IngelheimJardiance, Tradjenta | $16 | $46,33336 claims |
| PfizerEliquis | $42 | $33,81332 claims |
| Johnson & JohnsonXarelto | $19 | $15,16111 claims |
| AbbVieSynthroid | $128 | $1,98728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Hope
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.